1. Home
  2. TNGX vs OKE Comparison

TNGX vs OKE Comparison

Compare TNGX & OKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • OKE
  • Stock Information
  • Founded
  • TNGX 2014
  • OKE 1906
  • Country
  • TNGX United States
  • OKE United States
  • Employees
  • TNGX N/A
  • OKE N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • OKE Oil & Gas Production
  • Sector
  • TNGX Health Care
  • OKE Utilities
  • Exchange
  • TNGX Nasdaq
  • OKE Nasdaq
  • Market Cap
  • TNGX 351.2M
  • OKE 50.1B
  • IPO Year
  • TNGX N/A
  • OKE N/A
  • Fundamental
  • Price
  • TNGX $6.01
  • OKE $81.34
  • Analyst Decision
  • TNGX Strong Buy
  • OKE Buy
  • Analyst Count
  • TNGX 6
  • OKE 14
  • Target Price
  • TNGX $12.20
  • OKE $103.43
  • AVG Volume (30 Days)
  • TNGX 2.7M
  • OKE 3.8M
  • Earning Date
  • TNGX 08-06-2025
  • OKE 08-04-2025
  • Dividend Yield
  • TNGX N/A
  • OKE 5.09%
  • EPS Growth
  • TNGX N/A
  • OKE 18.10
  • EPS
  • TNGX N/A
  • OKE 5.11
  • Revenue
  • TNGX $40,990,000.00
  • OKE $24,960,000,000.00
  • Revenue This Year
  • TNGX N/A
  • OKE $29.67
  • Revenue Next Year
  • TNGX N/A
  • OKE $2.22
  • P/E Ratio
  • TNGX N/A
  • OKE $15.92
  • Revenue Growth
  • TNGX 10.09
  • OKE 39.15
  • 52 Week Low
  • TNGX $1.03
  • OKE $75.48
  • 52 Week High
  • TNGX $12.02
  • OKE $118.07
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 76.36
  • OKE 48.53
  • Support Level
  • TNGX $5.34
  • OKE $80.07
  • Resistance Level
  • TNGX $6.40
  • OKE $82.00
  • Average True Range (ATR)
  • TNGX 0.50
  • OKE 1.68
  • MACD
  • TNGX -0.02
  • OKE 0.08
  • Stochastic Oscillator
  • TNGX 84.08
  • OKE 51.72

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

About OKE ONEOK Inc.

Oneok is a diversified midstream service provider specializing in natural gas gathering, processing, storage, and transportation and natural gas liquids transportation and fractionation. It also operates a refined product and crude oil segment connecting producers, refiners, and consumers. Operations are in the midcontinent, Permian, and Rocky Mountain regions.

Share on Social Networks: